Illumina Inc. ($ILMN) Stock Forecast: Down 5.9% Today

What is Illumina Inc.?

Illumina Inc. (ILMN) is a leading company in the genomics industry, known for its innovative technologies in genomic sequencing and analysis. The company has been facing challenges in the market due to various factors impacting the biotech sector.

Why is Illumina Inc. going down?

ILMN stock is down 5.9% on Mar 27, 2026 14:12

• Illumina's stock experienced a bearish movement due to regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector, leading to softening demand in genomic sequencing and increased competition.
• The short-term corrective bearish wave, negative pressure from technical indicators like the 50-day SMA and overbought Stochastic indicators, contributed to the decline in Illumina's stock price.
• Despite positive news such as Nordea Investment Management AB significantly increasing its stake in Illumina and the company reporting strong Q4 earnings, the mixed analyst sentiment and challenges in the industry have put pressure on the stock.
• The launch of Illumina's TruPath™ Genome tool aims to provide deeper insights into complex genomic regions, showcasing the company's commitment to advancing genomic research amidst market challenges.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown

Illumina Inc. is facing significant challenges, including regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector. Despite a robust balance sheet and ongoing R&D investments, the company's stock is under pressure from softening demand in genomic sequencing, increased competition, and lingering legal ramifications from the Grail divestiture. Investors are closely watching if Illumina can successfully navigate these headwinds and recover its growth trajectory.

https://www.ad-hoc-news.de/boerse/ueberblick/illumina-inc-stock-faces-headwinds-amid-grail-divestiture-scrutiny-and/68977501

Illumina price gives in to negative pressure - Forecast today - 24-03-2026

Illumina's (ILMN) stock price experienced a decline due to a short-term corrective bearish wave and negative pressure from its 50-day SMA, coupled with overbought Stochastic indicators. Analysts predict further decline, targeting a key support level at $115.30 unless it breaks above $128.15. The article also provides bearish forecasts for Alibaba and Snap, and a bullish forecast for Western Digital.

https://www.economies.com/stocks/united-states-analysis/illumina-price-gives-in-to-negative-pressure---forecast-today---24-03-2026-125749

US Multiomic Market Set to Boom Rapidly, Witnessing Strong

Coherent Market Insights has released a new research study on the Global "US Multiomic Market" forecasting strong growth through 2033. The report segments the market by type (Genomics, Proteomics, Metabolomics) and applications (Precision Medicine, Drug Discovery, Clinical Research), and provides competitive and regional analysis. Key players include Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc.

https://www.openpr.com/news/4437722/us-multiomic-market-set-to-boom-rapidly-witnessing-strong

TruPath™ Genome enables deeper insight into complex genomic regions

This article introduces Illumina's TruPath™ Genome, a new tool designed to offer deeper insights into complex genomic regions. Steve Barnard explains how this approach addresses research challenges and enables comprehensive genome interpretation without needing changes to existing sequencing infrastructure. The technology aims to advance genomic research by providing more detailed data.

https://www.illumina.com/company/video-hub/U4l4GnIUsLw.html

Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN

Nordea Investment Management AB significantly increased its stake in Illumina, Inc. by 2,792.2% in Q4, acquiring 911,843 additional shares to hold a total of 944,500 shares valued at approximately $124.15 million. This move comes as Illumina reported Q4 earnings that beat estimates, with EPS of $1.35 and revenue of $1.16 billion, and issued promising FY2026 guidance. Analyst sentiment for Illumina is mixed, with an average "Hold" rating and an average price target of $129.69, despite some firms raising their targets to around $170.

https://www.marketbeat.com/instant-alerts/filing-nordea-investment-management-ab-has-12415-million-stake-in-illumina-inc-ilmn-2026-03-23/

Trending Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 6.3% Today

Rocket Companies Inc ($RKT) Stock Forecast: Down 5.0% Today

Broadcom Inc. ($AVGO) Stock Forecast: Up 5.9% Today

Gartner Inc. ($IT) Stock Forecast: Down 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.4% Today

Humana Inc. ($HUM) Stock Forecast: Up 8.8% Today

CVS Health Corporation ($CVS) Stock Forecast: Up 6.6% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 6.5% Today

Arista Networks Inc. ($ANET) Stock Forecast: Up 5.3% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 10.7% Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.1%

• The bullish movement in Illumina's stock could be attributed to the company's partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to launch the Billion Cell Atlas initiative. This ambitious project aims to map genetic perturbations in five billion human cells, providing valuable insights for drug discovery and precision medicine.
• The collaboration with major pharmaceutical companies highlights Illumina's commitment to advancing genomic research and its potential to revolutionize the field of AI-driven drug discovery.
• The emphasis on creating a comprehensive genetic dataset to accelerate drug discovery and improve target validation likely resonated positively with investors, driving the bullish market movement in Illumina's stock today.

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.01.2026 - ILMN Stock was down 12.3%

• Despite strong Q4 2025 earnings that surpassed expectations, Illumina's stock saw a notable decline following a cautious 2026 revenue outlook.
• Investor response suggests disappointment with the company's conservative forecast for the upcoming period, despite its previous strong performance.
• Illumina's strategic focus on core sequencing, multiomics scaling, and data/software expansion is contributing to its momentum. However, concerns around the subdued 2026 revenue guidance seemed to overshadow these accomplishments for investors.
• While the company remains optimistic about the growing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument in clinical settings, these positive prospects were unable to offset worries about future growth potential, resulting in a bearish trend for the stock.

06.01.2026 - ILMN Stock was down 9.6%

• Despite surpassing Q4 earnings forecasts, Illumina's stock trended bearishly due to its conservative 2026 revenue guidance, disappointing investors who were anticipating a more aggressive outlook.
• The market's response suggests that investors are evaluating Illumina's robust operational performance in Q4 against its unchanging annual revenue for 2025, which paralleled the previous year.
• Although Illumina offered a positive forecast for 2026, anticipating revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, the stock's decline indicates that investors possibly anticipated more ambitious future projections.
• The contrast between the company's solid financial performance and the market's reaction underscores the significance of managing investor expectations and articulating a compelling growth narrative for forthcoming results.

06.00.2026 - ILMN Stock was up 5.3%

• In spite of regulatory challenges and cautious sentiment from investors, Illumina demonstrated significant bullish momentum today.
• While receiving "hold" ratings from Wall Street Zen and Zacks Research, the company surpassed Q3 earnings projections and offered optimistic FY2025 guidance, resonating well with investors.
• The positive market response can be linked to hopeful investor sentiment regarding Illumina's anticipated recovery, supported by its strategic capital allocation and increasing demand for sequencing.
• Illumina's efforts to adapt to the AI era and consolidate its place in the genomics sector have instilled a sense of cautious optimism among investors and insiders about the company's future trajectory.

27.02.2026 - ILMN Stock was down 5.9%

• Illumina's stock experienced a bearish movement due to regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector, leading to softening demand in genomic sequencing and increased competition.
• The short-term corrective bearish wave, negative pressure from technical indicators like the 50-day SMA and overbought Stochastic indicators, contributed to the decline in Illumina's stock price.
• Despite positive news such as Nordea Investment Management AB significantly increasing its stake in Illumina and the company reporting strong Q4 earnings, the mixed analyst sentiment and challenges in the industry have put pressure on the stock.
• The launch of Illumina's TruPath™ Genome tool aims to provide deeper insights into complex genomic regions, showcasing the company's commitment to advancing genomic research amidst market challenges.

24.01.2026 - ILMN Stock was up 5.6%

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

05.10.2025 - ILMN Stock was up 5.3%

• Following the company's surpassing of its third-quarter guidance and the narrowing of its full-year revenue decline forecast, Illumina's stock rose by over 23%, indicating optimistic growth prospects.
• Investor sentiment towards Illumina turned positive, with notable investors showing confidence in the company's future performance.
• The third-quarter earnings report exceeded expectations, reporting adjusted earnings of $1.34 per share, surpassing consensus estimates and contributing to the stock's significant increase.
• Illumina's ability to outperform expectations in both earnings and revenue for the quarter ended September 2025 showcases robust operational performance and potential for further growth in the genomics sector.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.